COMMUNIQUÉS West-GlobeNewswire

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

02/05/2024 - 13:30

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, [...]

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

02/05/2024 - 13:30

First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024 (GLOBE [...]

Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO

02/05/2024 - 13:30

Dévoilement de données à long terme des parties 1 et 2 de l’essai clinique de phase I portant sur le sudocétaxel zendusortide dans les tumeurs solides La partie 3 de la phase I de l’essai sur le cancer de l’ovaire [...]

Biogen Reports Progress on Corporate Responsibility Priorities

02/05/2024 - 13:30

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced [...]

VitalHub Announces Q1 2024 Conference Call Date

02/05/2024 - 13:30

TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") (TSX: VHI) (OTCQX:VHIBF) is pleased to announce that it will release its financial results for its first quarter 2024 ended March 30 [...]

Quipt Home Medical Announces Normal Course Issuer Bid

02/05/2024 - 13:30

CINCINNATI, May 02, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced today [...]

Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor

02/05/2024 - 10:30

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]

Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing

02/05/2024 - 09:00

RetinAI Medical AG rebranded as Ikerian AG “Ikerian”, to spearhead development beyond ophthalmology, with wholly-owned subsidiary RetinAI U.S. Inc. “RetinAI” focused on the ophthalmology and optometry market. Ikerian’s [...]

Iktos announces the appointment of Roman Fleck as Chairman of the Board

02/05/2024 - 08:45

Paris (France), 2 nd May 2024 – Iktos , a company specialized in Artificial Intelligence for new drug design, announces the appointment of Roman Fleck as Chairman of the Board. Yann Gaston-Mathé steps down of his role [...]

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein

02/05/2024 - 08:30

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

02/05/2024 - 08:00

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and [...]

Director/PDMR Shareholding

02/05/2024 - 08:00

DXS INTERNATIONAL PLC Notification of Director / PDMR Dealing The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision [...]

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

02/05/2024 - 07:30

Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales [...]

Ipsen appoints Keira Driansky as EVP, President of North America

02/05/2024 - 07:30

PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13 [...]

Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord

02/05/2024 - 07:30

PARIS, FRANCE, 2 Mai 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondiale de spécialité, annonce aujourd'hui la nomination de Keira Driansky en tant que Vice-Présidente Exécutive, et Présidente [...]

IBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, US

02/05/2024 - 07:00

Louvain-La-Neuve, Belgium, 2 May 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy [...]

IBA signe un contrat avec Yale New Haven Health et Hartford HealthCare pour l’installation d’une solution de protonthérapie Proteus®ONE dans le Connecticut, aux États-Unis

02/05/2024 - 07:00

Louvain-la-Neuve, Belgique, le 2 mai 2024 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial de la technologie d’accélération de particules, annonce aujourd'hui avoir signé un contrat avec le Connecticut [...]

ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions

02/05/2024 - 07:00

EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and [...]

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

02/05/2024 - 07:00

May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]